Pharmaceuticals, Biotechnology and Life Sciences
Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and KT-333 continuing in Phase 1…
REDWOOD CITY, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) — Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive…
ERYTECH Announces Receipt of Nasdaq Notice Cambridge, MA (U.S.) and Lyon (France), October 13, 2022 – ERYTECH Pharma (Nasdaq &…
Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics,…
Highlights include data from non-clinical and microbiology programs and real-world patient use BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) — Paratek…
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…
WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) — Invivyd, (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect…
– Robust post-dosing changes continue to be seen in key markers associated with severity of disease – Pharmacodynamic data from…
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code…
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of…